NVO FDA calendar & decision history Novo Nordisk · 1 upcoming · 7 past FDA decisions
Upcoming FDA catalysts NVO · Dec 31, 2026 CagriSema (AM833) — Obesity / weight management FDA decision history (7) Mar 26, 2026✓ Approved Awiqli (insulin icodec-abae) i Mar 19, 2026✓ Approved Wegovy HD Mar 3, 2026✓ Approved Sogroya (somapacitan) - (REAL8 Dec 22, 2025✓ Approved FDA decision Oct 15, 2025✓ Approved FDA decision Aug 15, 2025✓ Approved FDA decision Jan 28, 2025✓ Approved FDA decision See the full 2026 PDUFA calendar → This page aggregates NVO's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio